Thyroid Cancer Treatments
Find Thyroid Cancer Treatments
Medications for Thyroid Cancer
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Thyroid Cancer.
Found 8 Approved Drugs for Thyroid Cancer
Liothyronine
Brand Names
Cytomel, Liomny
Liothyronine
Brand Names
Cytomel, Liomny
Form: Injection, Tablet
Method of administration: Oral, Intravenous
FDA approval date: May 08, 1956
Classification: l-Triiodothyronine
Liothyronine sodium injection (T 3 ) is indicated in the treatment of myxedema coma/precoma. Liothyronine sodium injection (T 3 ) can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef.
I-131
Brand Names
Volumex, Megatope
I-131
Brand Names
Volumex, Megatope
Form: Injection, Kit
Method of administration: Oral, Intravenous
FDA approval date: August 01, 1993
Volumex (Iodinated I 131 Allbumin injection) is indicated for use in determinations of total blood and plasma volumes and in protein turnover studies.
Doxil
Generic Name
DOXOrubicin
Doxil
Generic Name
DOXOrubicin
Form: Injection, Injectable
Method of administration: Intravenous, Intravitreal
FDA approval date: December 23, 1987
Classification: Anthracycline Topoisomerase Inhibitor
Doxorubicin is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer.
Sorafenib
Brand Names
Nexavar, Sorafenib Tosylate
Sorafenib
Brand Names
Nexavar, Sorafenib Tosylate
Form: Tablet
Method of administration: Oral
FDA approval date: December 20, 2005
Classification: Kinase Inhibitor
Sorafenib is a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma.
Caprelsa
Generic Name
Vandetanib
Caprelsa
Generic Name
Vandetanib
Form: Tablet
Method of administration: Oral
FDA approval date: July 25, 2011
Classification: Kinase Inhibitor
CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. ( 1 ) Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. ( 1 )
Showing 1-5 of 8
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances